TNF and inflammatory bowel disease: Therefore, the choice of treating firstly the IBD with biologics and then the HCV infection using antiviral therapy, could be one of the timing approaches, especially in patients rapidly needing biologics for an acute IBD, because of safety of biological drugs in HCV infected subjects and high rate of SVR after introducing antiviral therapy in patients treated with anti-TNF agents (Gupta et al., 2014; Koff, 2014; Degasperi et al., 2016; Ohta et al., 2016; European Association for the Study of the Liver, 2017; Ramos-Casals et al., 2017).